MK-3475A, PEMETREXED , MK-1084, MK-1084, CISPLATIN , CARBOPLATIN , MK-1084, MK-1084
MK-1084-007
Phase 3 small_molecule active
Quick answer
MK-3475A, PEMETREXED , MK-1084, MK-1084, CISPLATIN , CARBOPLATIN , MK-1084, MK-1084 for Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active